中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 5
May  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(5): 1143-1147

Research advances in the role of gut microbiota in chronic hepatitis B, chronic hepatitis C, and related liver diseases

DOI: 10.3969/j.issn.1001-5256.2022.05.035

  • Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Research funding:

National Science and Technology Major Project for Infectious Diseases of China (2017ZX10304402-002-00)

More Information
  • Corresponding author: WANG Baoju, bjwang73@163.com(ORCID: 0000-0001-6942-570X)
  • Received Date: 2021-12-28
  • Published Date: 2022-05-20
    Abstract
  • Hepatitis B virus infection and hepatitis C virus infection often progress to end-stage liver diseases such as liver cirrhosis, liver failure, and hepatocellular carcinoma, which endanger the life of patients. Recent studies have shown that gut microbiota are closely associated with chronic viral liver diseases. This article reviews the association of gut microbiota with chronic hepatitis B (CHB), chronic hepatitis C (CHC), and their related liver diseases and the research advances in therapies targeting gut microbiota against CHB and its related liver diseases, in order to provide more ideas for the clinical treatment of CHB, CHC, and their related liver diseases.

     

    • FullText(HTML)
  • loading
    • References(49)
  • [1]
    EL-SERAG HB. Epidemiology of viral hepatitis and hepatocellular carcinoma[J]. Gastroenterology, 2012, 142(6): 1264-1273. e1. DOI: 10.1053/j.gastro.2011.12.061.
    [2]
    MILOSEVIC I, VUJOVIC A, BARAC A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: A review of the literature[J]. Int J Mol Sci, 2019, 20(2): 395. DOI: 10.3390/ijms20020395.
    [3]
    LEY RE, PETERSON DA, GORDON JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine[J]. Cell, 2006, 124(4): 837-848. DOI: 10.1016/j.cell.2006.02.017.
    [4]
    UBEDA C, DJUKOVIC A, ISAAC S. Roles of the intestinal microbiota in pathogen protection[J]. Clin Transl Immunology, 2017, 6(2): e128. DOI: 10.1038/cti.2017.2.
    [5]
    WHO. World Health Organization Fact Sheet[EB/OL]. [2022-02-12]. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b, 2021.
    [6]
    LIU J, LIANG W, JING W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469.
    [7]
    WANG J, WANG Y, ZHANG X, et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients[J]. Front Microbiol, 2017, 8: 2222. DOI: 10.3389/fmicb.2017.02222.
    [8]
    ZENG Y, CHEN S, FU Y, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma[J]. J Viral Hepat, 2020, 27(2): 143-155. DOI: 10.1111/jvh.13216.
    [9]
    ZHU Q, XIA P, ZHOU X, et al. Hepatitis B virus infection alters gut microbiota composition in mice[J]. Front Cell Infect Microbiol, 2019, 9: 377. DOI: 10.3389/fcimb.2019.00377.
    [10]
    CHOU HH, CHIEN WH, WU LL, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota[J]. Proc Natl Acad Sci U S A, 2015, 112(7): 2175-2180. DOI: 10.1073/pnas.1424775112.
    [11]
    CHEN Z, XIE Y, ZHOU F, et al. Featured gut microbiomes associated with the progression of chronic hepatitis B disease[J]. Front Microbiol, 2020, 11: 383. DOI: 10.3389/fmicb.2020.00383.
    [12]
    GEHRING AJ, PROTZER U. Targeting innate and adaptive immune responses to cure chronic HBV infection[J]. Gastroenterology, 2019, 156(2): 325-337. DOI: 10.1053/j.gastro.2018.10.032.
    [13]
    GUO W, ZHOU X, LI X, et al. Depletion of gut microbiota impairs gut barrier function and antiviral immune defense in the liver[J]. Front Immunol, 2021, 12: 636803. DOI: 10.3389/fimmu.2021.636803.
    [14]
    URDANETA V, CASADESÚS J. Interactions between bacteria and bile salts in the gastrointestinal and hepatobiliary tracts[J]. Front Med (Lausanne), 2017, 4: 163. DOI: 10.3389/fmed.2017.00163.
    [15]
    SAYIN SI, WAHLSTRÖM A, FELIN J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist[J]. Cell Metab, 2013, 17(2): 225-235. DOI: 10.1016/j.cmet.2013.01.003.
    [16]
    WANG X, CHEN L, WANG H, et al. Modulation of bile acid profile by gut microbiota in chronic hepatitis B[J]. J Cell Mol Med, 2020, 24(4): 2573-2581. DOI: 10.1111/jcmm.14951.
    [17]
    KOH A, de VADDER F, KOVATCHEVA-DATCHARY P, et al. From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites[J]. Cell, 2016, 165(6): 1332-1345. DOI: 10.1016/j.cell.2016.05.041.
    [18]
    BAJAJ JS, REDDY KR, O'LEARY JG, et al. Serum levels of metabolites produced by intestinal microbes and lipid moieties independently associated with acute-on-chronic liver failure and death in patients with cirrhosis[J]. Gastroenterology, 2020, 159(5): 1715-1730. e12. DOI: 10.1053/j.gastro.2020.07.019.
    [19]
    WHO. World Health Organization Fact Sheet[EB/OL]. [2022-02-12]https://www.who.int/news-room/fact-sheets/detail/hepatitis-c, 2021.
    [20]
    INOUE T, NAKAYAMA J, MORIYA K, et al. Gut dysbiosis associated with hepatitis C virus infection[J]. Clin Infect Dis, 2018, 67(6): 869-877. DOI: 10.1093/cid/ciy205.
    [21]
    WELLHÖNER F, DÖSCHER N, WOELFL F, et al. Eradication of chronic HCV infection: Improvement of dysbiosis only in patients without liver cirrhosis[J]. Hepatology, 2021, 74(1): 72-82. DOI: 10.1002/hep.31700.
    [22]
    PÉREZ-MATUTE P, ÍÑIGUEZ M, VILLANUEVA-MILLÁN MJ, et al. Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients[J]. Eur J Intern Med, 2019, 67: 47-58. DOI: 10.1016/j.ejim.2019.06.005.
    [23]
    PONZIANI FR, PUTIGNANI L, PARONI STERBINI F, et al. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2018, 48(11-12): 1301-1311. DOI: 10.1111/apt.15004.
    [24]
    SULTAN S, EL-MOWAFY M, ELGAML A, et al. Alterations of the treatment-naive gut microbiome in newly diagnosed hepatitis C virus infection[J]. ACS Infect Dis, 2021, 7(5): 1059-1068. DOI: 10.1021/acsinfecdis.0c00432.
    [25]
    SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): An update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3.
    [26]
    LI L, WU Z, MA W, et al. Changes in intestinal microflora in patients with chronic severe hepatitis[J]. Chin Med J (Engl), 2001, 114(8): 869-872.
    [27]
    YAO X, YU H, FAN G, et al. Impact of the gut microbiome on the progression of hepatitis B virus related acute-on-chronic liver failure[J]. Front Cell Infect Microbiol, 2021, 11: 573923. DOI: 10.3389/fcimb.2021.573923.
    [28]
    WANG K, ZHANG Z, MO ZS, et al. Gut microbiota as prognosis markers for patients with HBV-related acute-on-chronic liver failure[J]. Gut Microbes, 2021, 13(1): 1-15. DOI: 10.1080/19490976.2021.1921925.
    [29]
    DUPONT HL. Review article: the antimicrobial effects of rifaximin on the gut microbiota[J]. Aliment Pharmacol Ther, 2016, 43 (Suppl 1): 3-10. DOI: 10.1111/apt.13434.
    [30]
    SHARMA BC, SHARMA P, LUNIA MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy[J]. Am J Gastroenterol, 2013, 108(9): 1458-1463. DOI: 10.1038/ajg.2013.219.
    [31]
    KANG SH, LEE YB, LEE JH, et al. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy[J]. Aliment Pharmacol Ther, 2017, 46(9): 845-855. DOI: 10.1111/apt.14275.
    [32]
    GOEL A, RAHIM U, NGUYEN LH, et al. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis[J]. Aliment Pharmacol Ther, 2017, 46(11-12): 1029-1036. DOI: 10.1111/apt.14361.
    [33]
    BAJAJ JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis[J]. Aliment Pharmacol Ther, 2016, 43 (Suppl 1): 11-26. DOI: 10.1111/apt.13435.
    [34]
    BAJAJ JS, HEUMAN DM, SANYAL AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy[J]. PLoS One, 2013, 8(4): e60042. DOI: 10.1371/journal.pone.0060042.
    [35]
    CHAUHAN A, KUMAR R, SHARMA S, et al. Fecal microbiota transplantation in hepatitis B e antigen-positive chronic hepatitis B patients: A pilot study[J]. Dig Dis Sci, 2021, 66(3): 873-880. DOI: 10.1007/s10620-020-06246-x.
    [36]
    REN YD, YE ZS, YANG LZ, et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy[J]. Hepatology, 2017, 65(5): 1765-1768. DOI: 10.1002/hep.29008.
    [37]
    BAJAJ JS, KASSAM Z, FAGAN A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial[J]. Hepatology, 2017, 66(6): 1727-1738. DOI: 10.1002/hep.29306.
    [38]
    BAJAJ JS, SALZMAN N, ACHARYA C, et al. Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis[J]. JCI Insight, 2019, 4(24) : e133410. DOI: 10.1172/jci.insight.133410.
    [39]
    DEFILIPP Z, BLOOM PP, TORRES SOTO M, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant[J]. N Engl J Med, 2019, 381(21): 2043-2050. DOI: 10.1056/NEJMoa1910437.
    [40]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol, 2018, 34(10): 2076-2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007.

    中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南[J]. 临床肝胆病杂志, 2018, 34(10): 2076-2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007.
    [41]
    ZHENG N, YU LL, CAO Z. Effect of treatment with viable bifidobacterium quadruple on liver function, cytokines and intestinal flora in patients with liver cirrhosis[J]. Med & Pharm J Chin PLA, 2020, 32(8): 36-39. DOI: 10.3969/j.issn.2095-140X.2020.08.009.

    郑能, 于力力, 曹志. 双歧杆菌四联活菌治疗对肝硬化患者肝功能、细胞因子及肠道菌群的影响[J]. 解放军医药杂志, 2020, 32(8): 36-39. DOI: 10.3969/j.issn.2095-140X.2020.08.009.
    [42]
    DHIMAN RK, RANA B, AGRAWAL S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial[J]. Gastroenterology, 2014, 147(6): 1327-1337. e3. DOI: 10.1053/j.gastro.2014.08.031.
    [43]
    XIA X, CHEN J, XIA J, et al. Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis[J]. J Int Med Res, 2018, 46(9): 3596-3604. DOI: 10.1177/0300060518776064.
    [44]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [45]
    YAN H, PENG B, LIU Y, et al. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide[J]. J Virol, 2014, 88(6): 3273-3284. DOI: 10.1128/JVI.03478-13.
    [46]
    MOUZANNAR K, FUSIL F, LACOMBE B, et al. Farnesoid X receptor-α is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo[J]. FASEB J, 2019, 33(2): 2472-2483. DOI: 10.1096/fj.201801181R.
    [47]
    ZHANG DY, ZHU L, LIU HN, et al. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease[J]. Drug Des Devel Ther, 2019, 13: 2249-2270. DOI: 10.2147/DDDT.S207277.
    [48]
    FRIEDMAN ES, LI Y, SHEN TD, et al. FXR-dependent modulation of the human small intestinal microbiome by the bile acid derivative obeticholic acid[J]. Gastroenterology, 2018, 155(6): 1741-1752. e5. DOI: 10.1053/j.gastro.2018.08.022.
    [49]
    MARKHAM A, KEAM SJ. Obeticholic acid: First global approval[J]. Drugs, 2016, 76(12): 1221-1226. DOI: 10.1007/s40265-016-0616-x.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (560) PDF downloads(62) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return